We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Smartphone Attachment Rapidly Determines Urine Albumin Level and Transmits the Result

By LabMedica International staff writers
Posted on 04 Sep 2013
The potential value of smartphone applications in the field of in vitro diagnosis (IVD) has been emphasized by the development of a smartphone attachment that rapidly determines the level of albumin in a patient's urine and transmits the results to a database or healthcare center.

The light-weight (approximately 148 grams) and compact Albumin Tester attachment developed by investigators at the University of California, Los Angeles (USA) is mechanically installed on the existing camera unit of a smartphone, where test and control tubes are inserted from the side and are excited by a battery powered laser diode.

The excitation beam, after probing the urine sample in the test tube, interacts with the control tube, and the resulting fluorescent emission is collected perpendicular to the direction of the excitation, where the smartphone camera captures the images of the fluorescent tubes through the use of an external plastic lens that is inserted between the sample and the camera lens. More...


The acquired fluorescent images of the sample and control tubes are digitally processed within one second through an Android application running on the same smartphone for quantification of albumin concentration in the urine specimen. Test results are then transmitted by the smartphone to a database or healthcare provider.

A study published in the August 9, 2013, online edition of the journal Lab on a Chip revealed that by following a simple sample preparation approach, which took about five minutes per test (including the incubation time), the investigators demonstrated that the detection limit of the sensing platform was five to 10 micrograms per milliliter (which is more than three times lower than clinically accepted normal range) in buffer as well as urine samples.

The investigators suggested that an automated albumin-testing tool running on a smartphone could be useful for early diagnosis of kidney disease or for monitoring of chronic patients, especially those suffering from diabetes, hypertension, and/or cardiovascular diseases.

"Albumin testing is frequently done to assess kidney damage, especially for diabetes patients," said senior author Dr. Aydogan Ozcan, professor of electrical and bio-engineering at the University of California, Los Angeles. "This device provides an extremely convenient platform for chronic patients at home or in remote locations where cell phones work."

Related Links:

University of California, Los Angeles



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.